EDITORIAL

The Dexamethasone Suppression Test
In this issue of the Journal Drs. V. Prabhu and N. el-Guebaly (I) review the complex problems surrounding cortisol secretion and the dexamethasone suppression test in affective disorders. These issues are part of a story which has an interesting background. A close association between hormonal imbalance and psychiatric disorders has been suspected by clinicians for many years. Marking the end of an early era, Mannfred Bleuler in 1966 summarized his major contribution to the happy marriage between the hormones and the mind (2) , and concluded that a wide variety of psychiatric disorders, particularly affective disorders, are well documented among patients with endocrine illnesses; however, although hormonal imbalance in psychiatric patients may be suspected it cannot be quantified with existing methods. Shortly thereafter dramatic developments took place in psychoendocrinologyand major advances were made, particularly in the determination of hormones in biological fluids. This technical progress facilitated systematic neuroendocrine research in affective disorders and several other psychiatric states. Evidence has quickly accumulated which indicates that endocrine alteration may be concurrent with some psychiatric disorders. For example, in "endogenous depression" there appears a rise in plasma cortisol which may remain evident even after administration of dexamethasone.
Most attention among these exciting developments has to date been attracted by the promise to diagnose some melancholias by.a relatively simple laboratory test: dexamethasone suppression (DST). Prominent among those who have employed the DST in psychiatry is B.J. Carroll who with M. Feinberg, M. Steiner and co-workers has done much to standardize the DST and develop it for use in psychiatry (3). The timing for this development appears propitious indeed. At a time when psychiatry is again moving closer to medicine, and stressing the elements of a medical model in its concepts, there is almost a magical strengthening of the hope that a psychiatristclinician may be able to utilize laboratory-generated numbers not only in therapy -remember lithium and antidepressants levels -but also in diagnosis.
Over the past couple of years a number of articles have been published in direct support of the diagnostic value of the DST. Furthermore, there is a strong tendency to interpret a positive DST finding as an indicator of central norepinephrine deficiency, even though such a conclusion is only speculative. When reading over the recently mushrooming literature on psychiatric use of the DST it may be useful to keep in mind a warning from the history of science that any new finding which fits the prevailing 595 paradigm is quickly supported by a flurry of additional observations (4) .
In this issue Dr. el-Guebaly and associates (1) put the complex problem of cortisol secretion and the DST in an interesting perspective. While they underline how encouraging the results of recent clinical applications have been, they stress the lack of well controlled, sequential studies and the need for caution in interpretation. They remind us of a number of methodologically rigorous studies on cortisol carried out in the 50's and 60's and contrast those cautious findings with the present wave of less reserved enthusiasm. While their comments are formulated at a general level, they have specific, direct implications for the use of cortisol plasma levels in a diagnostic test. The reminder of Dr. el-Guebaly about earlier cortisol findings serves a very useful purpose as it forces us to reconsider in connection with the DST the issues of agespecific and sex-specific standardization, the role of environmental stresses and the need for larger samples and more outpatient studies.
The authors' plea against premature closure on this issue and for keeping the potential usefulness of the DST as a diagnostic and management tool open to further scrutiny gets full support from several recent presentations and publications. Recent reports raise questions about the specificity of the DST in melancholia, as the test has been found positive in 15-46% of subjects who were not depressed and who belonged to groups as diverse as dementias, obsessive compulsive disorder, abstaining alcoholics and even healthy volunteers (5, 6) . Perhaps more importantly, negative results of the DST were changed to positive by a relatively small weight loss in the same individuals (6), and positive results turned negative simply by repeating the DST a few days after admission, without any change in the clinical state or treatment (7) . In addition, it is possible that the positivity of the test also increases as a function of advancing age, and this again puts more weight on Dr. el-Guebaly and co-workers' comments.
While it is conceivable that the positive DST may delineate a new, useful subgroup of affective disorders for which Carroll has revitalized the term melancholia, there is also a potential for circular thinking in this approach. There is a danger that this search for a biological marker for depression may turn into a search for a depression matching this biological marker (that is, positive DST). We could escape this potentially vicious circle by finding some other clinically useful characteristics in patients with positive DST such as their response to particular treatment. Thus, it has been suggested several times that patients with positive DST respond better to antidepressants; however, the history of research on antidepressant response has to make everyone skeptical of the reproducibility of such findings. It has never been really possible to differentiate between patients who improve specifically because of an antidepressant drug and those who benefit from placebo effects or who recover spontaneously. The effects oflithium stabilization on the other hand are more predictable. It would therefore support the clinical value of the test if patients with positive DST fared particulary well on stabilizing lithium. However, no significant association has been found between the positive DST and a good response to stabilizing lithium treatment (8, 9) .
Clearly, intensive search for biological markers in psychiatry will not stop here and should not. The fact that the solution to the problem of a clinically useful biological marker continues to elude psychiatry should not make us give up, but intensify the search. The lessons given in the article of Dr. el-Guebaly et al. suggest that we should not neglect learning from history and should be cautious particularly about the dangers of abuse of biological markers. A premature jump from a research springboard into the murky waters of a shallow clinical pool looms as particularly dangerous.
It appears that the DST remains an extremely valuable and promising research tool which can in the future substantially contribute to important issues (for example: the subclassification of affective disorders). However, much more investigational work needs to be done, especially along the lines stressed in this issue. While the DST is clearly a valid research tool, recent studies suggest . that its specificity may not be as high as needed for useful diagnostic tests. It would be premature -and it might be at times dangerous -to use the results of the DST as a major lead for treatment decisions. Unfortunately, the rules of the game have not been changed yet; useful treatment decisions have to remain based on a careful clinical assessment of each patient that is as comprehensive as possible. Much more information has to be utilized than just the results of a laboratory test.
In the long run the value of the DST will be appreciated in many respects. To this point the DST has certainly served as a tremendous stimulus for research and for rethinking our field, as the papers by Dr. el-Guebaly et al. clearly documents.
